Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review
Annals of Clinical and Translational Neurology · 2024-04 · 11 (4) · 842-855
DOI: 10.1002/acn3.52017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 16.02.2024. Verfasst von Patricia K Coyle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Stony Brook Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA. Hauptthemen laut MEDLINE: Multiple Sclerosis, Sphingosine 1 Phosphate Receptor Modulators. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Four sphingosine 1‐phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these S1P receptor modulators, with an emphasis on similarities and differences. Efficacy data from the pivotal clinical trials are generally similar for the four agents. However, because no head‐to‐head clinical studies were conducted, direct efficacy comparisons cannot be made. Based on the adverse event profile of S1P receptor modulators, continued and regular monitoring of patients during treatment will be instructive. Notably, the authors recommend paying attention to the cardiac monitoring guidelines for these drugs, and when indicated screening for macular edema and cutaneous malignancies before starting treatment. To obtain the best outcome, clinicians should choose the drug based on disease type, history, and concomitant medications for each patient. Real‐world data should help to determine whether there are meaningful differences in efficacy or side effects between these agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Stony Brook Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.
- University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
- Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
- Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, USA.
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Bruce A C Cree
Förderung
- Bristol Myers Squibb
Zitieren
APA
Coyle, P. K., Freedman, M. S., Cohen, B. A., Cree, B. A. C., & Markowitz, C. E. (2024). Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review. Annals of Clinical and Translational Neurology, 11(4), 842-855. https://doi.org/10.1002/acn3.52017
Vancouver
Coyle PK, Freedman MS, Cohen BA, Cree BAC, Markowitz CE. Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review. Annals of Clinical and Translational Neurology. 2024;11(4):842-855. doi:10.1002/acn3.52017
BibTeX
@article{Coyle2024,
author = {Coyle, Patricia K and Freedman, Mark S and Cohen, Bruce A and Cree, Bruce A C and Markowitz, Clyde E},
title = {Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
volume = {11},
number = {4},
pages = {842--855},
doi = {10.1002/acn3.52017}
}
EUVIMED